Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.
Think of Farxiga (dapagliflozin) as similar to Invokana (canagliflozin). They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
Both lower A1C by about 1%...decrease weight by about 4 to 7 pounds...modestly lower BP...and slightly increase LDL cholesterol.